Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer

Integrated multidisciplinary care (MDC) is essential for the optimized management of patients with prostate cancer (PCa) due to the complexity of the disease and increasing availability of novel diagnostic and therapeutic options with novel mechanisms of action [1,2]. MDC enables dynamic discussions about key diagnostic steps, pre-treatment risk classification, and therapeutic options [3,4]. Other benefits include training opportunities for healthcare professionals (HCPs), lowering physician bias, increased patient engagement, promoting racial equity, and improving shared decision-making [5-8].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research